Vanguard Global Advisers
SRPT icon

Vanguard Global Advisers’s Sarepta Therapeutics SRPT Stock Holding History

Vanguard Global Advisers’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.06M Sell
114,655
-14,175
-11% -$268K ﹤0.01% 1245
2026
Q1 		$2.8M Buy
+128,830
New +$2.49M ﹤0.01% 995

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Global Advisers's SRPT Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Sarepta Therapeutics (SRPT) stake by 11% in Q2 2026, selling an estimated $268K and leaving 114,655 shares worth $2.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1245.

Vanguard Global Advisers first reported a position in SRPT in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.8M in Q1 2026. 316 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Vanguard Global Advisers held 114,655 shares of Sarepta Therapeutics worth $2.06M as of Q2 2026.
  • Vanguard Global Advisers sold 14,175 Sarepta Therapeutics shares in Q2 2026, an estimated $268K.
  • Sarepta Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1245 holding.
  • Vanguard Global Advisers first reported a position in Sarepta Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Sarepta Therapeutics position peaked at $2.8M in Q1 2026.
  • 316 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.